• 諮詢熱線+852 3480 8393

Logo
  • 首頁
  • 公司介紹
    • 背景
    • 免疫治療日本
    • 免疫治療香港
    • 腫瘤科醫生
  • 免疫細胞治療
    • 免疫細胞治療/自體免疫療法
    • 樹突狀細胞/DC疫苗療法
    • 自然殺傷細胞/NK細胞療法
    • 淋巴因子活化殺傷細胞(殺手T細胞)療法
    • 免疫治療成功率
    • 免疫治療副作用
    • 免疫治療費用
  • 醫生介紹
    • 日本
    • 香港
  • 癌症預防/防復發
    • 癌症復發率
    • 癌症預防
  • 新聞及臨床報告
    • 新聞
    • 臨床醫學報告
  • 聯絡我們

新聞及臨床報告

  • 首頁
  • 新聞及臨床報告
  • 臨床醫學報告
首頁 > 新聞及臨床報告 > 臨床醫學報告 > NK cell-based cancer immunotherapy: from basic biology to clinical development

NK cell-based cancer immunotherapy: from basic biology to clinical development

  • Journal of Hematology & Oncology
  • 2022-06-17
  • 0 次瀏覽

https://jhoonline.biomedcentral.com/articles/10.1186/s13045-020-01014-w 


Abstract

Natural killer (NK) cell is a specialized immune effector cell type that plays a critical role in immune activation against abnormal cells. Different from events required for T cell activation, NK cell activation is governed by the interaction of NK receptors with target cells, independent of antigen processing and presentation. Due to relatively unsophisticated cues for activation, NK cell has gained significant attention in the field of cancer immunotherapy. Many efforts are emerging for developing and engineering NK cell-based cancer immunotherapy. In this review, we provide our current understandings of NK cell biology, ongoing pre-clinical and clinical development of NK cell-based therapies and discuss the progress, challenges, and future perspectives.


Source: Liu, S., Galat, V., Galat4, Y. et al. NK cell-based cancer immunotherapy: from basic biology to clinical development. J Hematol Oncol 14, 7 (2021). https://doi.org/10.1186/s13045-020-01014-w

上一篇:Targeted Cancer Therapy by Dendritic Cell Vaccine 下一篇:WT1 (Wilms' Tumor Gene 1): Biology and Cancer Immunotherapy

欄目分類

  • 新聞 7
  • 臨床醫學報告 13

熱門文章

  • Targeting dendritic cells in pancreatic ductal adenocarcinoma
    2022-06-17
  • Modified Immunotherapy Approach Shows Promise for Leukemia Subscribe
    2022-06-17
  • Dendritic cell activation enhances anti-PD-1 mediated immunotherapy against glioblastoma
    2022-06-17
  • Targeted Cancer Therapy by Dendritic Cell Vaccine
    2022-06-17
  • Dendritic Cell–Based Immunotherapy: State of the Art and Beyond
    2022-06-17
  • Enhancing Dendritic Cell Therapy in Solid Tumors with Immunomodulating Conventional Treatment
    2022-06-17
  • NK cell-based cancer immunotherapy: from basic biology to clinical development
    2022-06-17
  • WT1 (Wilms' Tumor Gene 1): Biology and Cancer Immunotherapy
    2022-06-17
  • Cancer immunotherapy via dendritic cells
    2022-05-05
Logo
  • 郵箱:info@asiaimmune.com
  • 電話:+852 3480 8393

免疫細胞治療

  • 免疫細胞治療/自體免疫療法
  • 樹突狀細胞/DC疫苗療法
  • 自然殺傷細胞/NK細胞療法
  • 淋巴因子活化殺傷細胞(殺手T細胞)療法
  • 免疫治療成功率
  • 免疫治療副作用
  • 免疫治療費用

合作機構

  • 日本新橫濱加藤醫院

公司地址

  • 九龍尖沙咀漢口道28號亞太中心8樓812室
  • +852 3480 8393

Copyright © 2022. Designed by Asia Immunotherapy Company Limited.